Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > More evidence-based info on off-patent oncology drugs
  • News

More evidence-based info on off-patent oncology drugs

  • 2 March 2020
  • Editorial Staff
More evidence-based info on off-patent oncology drugs
Total
0
Shares
0
0
0
0
0

The American Association for Cancer Research (AACR) has offered help to the U.S. Food and Drug Administration (FDA) on its ambitious Project Renewal, that aims to evaluate accumulated scientific evidence on safety and efficacy of long-standing off-patent oncology drugs, so to update labeling information.

Over time, drug labeling becomes outdated as new information becomes available in the post-marketing setting, so the FDA decided in 2018 to launch Project Renewal to keep generic oncology product labeling up to date on a more frequent basis. In its first year, Project Renewal has developed a set of repeatable processes and procedures to evaluate evidence from published literature to inform regulatory decisions for updated product labeling of older oncology drugs, according to a joint announcement release by AACR and FDA.

“Patients and health care providers rely on accurate medical product labeling to inform care and treatment decisions.” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence. “We are pleased that the American Association for Cancer Research is joining Project Renewal, highlighting our goal to add value to the labeling update process by engaging the oncology community, generating awareness of the importance of FDA product labeling, and creating educational opportunities for clinical and basic cancer scientists as well as oncology fellows to learn how the FDA reviews evidence that informs product labeling.”

“The AACR is very proud to work with the FDA on this exciting project that has the potential to help oncologists in their decision making and, most importantly, to guide treatment decisions based on scientific evidence for the benefit of cancer patients,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR.

 

The key goals of Project Renewal

  • Develop repeatable processes
  • Use published data
  • Engage with oncology community
  • Foster educational experiences
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • AACR
  • FDA
  • off-patent
  • oncology drugs
  • project renewal
Editorial Staff

Previous Article
  • News

A step forward in prostate cancer screening optimisation

  • 26 February 2020
  • Elena Riboldi
View Post
Next Article
  • Articles
  • Medicine

How to make precision drugs that work better

  • 2 March 2020
  • Anna Wagstaff
View Post
You May Also Like
View Post
  • News

Multicomponent prevention strategy reduces risk of cancer

  • Janet Fricker
  • 20 May 2022
View Post
  • News

Lumpectomy as effective as mastectomy in young breast cancer patients

  • Janet Fricker
  • 13 May 2022
View Post
  • News

Multi organ chip could facilitate personalised cancer therapy 

  • Janet Fricker
  • 12 May 2022
View Post
  • News

100,000 Genomes Project pinpoints new cancer genetic culprits

  • Janet Fricker
  • 29 April 2022
View Post
  • News

IL-6 provides missing link between exercise and colon cancer protection

  • Janet Fricker
  • 28 April 2022
View Post
  • News

CAR T-cell therapy shows efficacy in solid tumours

  • Janet Fricker
  • 20 April 2022
View Post
  • News

No link between brain tumours and ‘usual’ use of mobile phones

  • Janet Fricker
  • 14 April 2022
View Post
  • News

Radiologists urged to report breast arterial calcification for CVD prevention

  • Janet Fricker
  • 30 March 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Multicomponent prevention strategy reduces risk of cancer
    • 20 May 2022
  • Lumpectomy as effective as mastectomy in young breast cancer patients
    • 13 May 2022
  • Multi organ chip could facilitate personalised cancer therapy 
    • 12 May 2022
  • 100,000 Genomes Project pinpoints new cancer genetic culprits
    • 29 April 2022
  • IL-6 provides missing link between exercise and colon cancer protection
    • 28 April 2022
Article
  • What can we expect from mRNA cancer vaccines?
    • 13 May 2022
  • Sri Lanka cancer care hit by foreign currency crisis
    • 6 May 2022
  • From social determinants to cancer outcomes: the cell biology behind the disparities
    • 29 April 2022
Latest printed issue
Social

Would you follow us ?

Contents
  • Message from a Ukrainian oncologist: Please prioritise my patients ‒ if you don’t who will?
    • 19 April 2022
  • Pandemics, War, Reconstruction and the Duty of Medicine and Science
    • 4 April 2022
  • Crisis in the Ukraine: we can help by doing what we do best
    • 4 March 2022
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Piazza Indipendenza 2, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.